Can an inhaled powder calm the painful Cold-Finger attacks of scleroderma?
NCT ID NCT07748000
First seen Aug 05, 2026 · Last updated Aug 07, 2026 · Updated 2 times
Summary
This study tests an inhaled powder called LIQ861 (treprostinil) in adults with scleroderma who have frequent, painful Raynaud's attacks—episodes where fingers or toes turn color and become numb or tingly. About 75 participants will be randomly assigned to receive either a dose that gradually increases or a fixed low dose, to see which doses are safe and comfortable. The study also looks at whether the treatment reduces the number, severity, and impact of these attacks.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- LIQ861 (treprostinil) inhalation powder
- What this could lead to
- If it works, this could offer a new way to reduce the frequency and severity of painful Raynaud's attacks in people with scleroderma, improving daily comfort and quality of life.
- What could go wrong
- This is an early (phase 2) study with a small number of participants, so results may not apply broadly. The treatment may cause side effects or may not effectively reduce attacks.
Why investors are watching
Liquidia is testing LIQ861, an inhaled powder form of treprostinil, in patients with systemic sclerosis who have frequent Raynaud's attacks. This phase 2a study aims to find safe and tolerable doses, and it also tracks whether the drug reduces the number and severity of attacks. For a small company, this readout matters because it could expand LIQ861's use beyond its current focus into a rare disease with few treatment options.
If it works: If the trial shows LIQ861 is well tolerated and reduces Raynaud's attacks, Liquidia could gain a new market in systemic sclerosis. That would broaden its product pipeline and strengthen its position as a specialty drug developer.
If it fails: The trial could fail to show a clear benefit or reveal safety issues, which would set back Liquidia's plans for this drug. Trials in rare diseases often miss their goals, so a negative result would likely hurt the company's prospects.
AI-written from the trial record. Speculative, and not investment advice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 75 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Oct 2026
An estimate. Start dates often move.
- Expected to finish
-
Mar 2027
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Male or female ≥18 years of age * Classification of SSc per the 2013 ACR/EULAR criteria. * Diagnosis or history of Raynaud's phenomenon * Minimum of 12 (maximum 100) symptomatic RP attacks documented in the ePRO diary over ≥4 separate days Exclusion Criteria: * ≥3 digital ulcers at screening; a new digital ulcer between screening and randomization; gangrene or amputation within 6 months; digital ulcer infection within 3 months. * History of cervical/digital sympathectomy or hand botulinum toxin injections within 90 days (or planned during the study). * Clinically significant bleeding risk, coagulation disorder, or platelet count \<100 x 10\^9/L. * Known WHO Group 1-5 pulmonary hypertension; significant obstructive (FEV1 \<65%) or restrictive (FVC \<60%) lung disease; need for supplemental oxygen; severe asthma. * Severe uncontrolled hypertension (SBP ≥160 and/or DBP \>100 mmHg) or severe hypotension (SBP \<85 mmHg). * Any parenteral, inhaled, or oral prostacyclin or prostacyclin receptor agonist within 12 weeks of screening; initiation/dose change of vasodilators within 4 weeks of screening; non-topical CYP2C8 inhibitors/inducers (unless discontinued for \>5 half-lives before randomization).
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Raynaud's phenomenon secondary to systemic sclerosis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.